{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:41Z","timestamp":1790960561118,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023-153094OB-I00"],"award-info":[{"award-number":["PID2023-153094OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Saf. Regul."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Current individual case safety report (ICSR) databases contain almost 56 million unique spontaneous declarations of drug-event associations by health professionals but also by patients themselves. These databases have become a useful source for detecting signals of disproportionate reporting (SDR). However, since health professionals use a medical jargon that is often distant from the more colloquial terms used by patients, they usually report more frequently certain adverse events than patients and <jats:italic>vice versa<\/jats:italic>. The main objective of this work is to illustrate the existence of different reporting patterns among drugs within a class and to analyze their potential impact on SDR detection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Four ICSR databases were considered, namely, FAERS, VAERS, JADER, and VigiBase, with reports up until March 2024. They were all integrated in a single database following a careful deduplication and COVID-19 correction protocol. Measures of reporting odds ratio, proportional reporting ratio and empirical Bayesian geometric mean were used to evaluate disproportionate reporting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The reporting patterns of four marketed oncology drugs, namely, olaparib, rucaparib, niraparib, and talazoparib, and an investigational drug, veliparib, were compared to those of a diverse set of eight clinically observed SDR, namely, fatigue, asthenia, anaemia, thrombocytopenia, neutropenia, insomnia, intestinal obstruction, and pneumonitis. The source pattern analysis revealed that olaparib and talazoparib are most frequently reported by physicians, and physicians are the main reporters of events such as neutropenia and pneumonitis, predisposing these events to be detected as SDR for those PARP inhibitors. In contrast, rucaparib and niraparib are most frequently reported by American consumers, and American consumers are the main reporters of events such as insomnia and intestinal obstruction, facilitating their detection as SDR for those two drugs. SDR detection was found to be robust to ICSR data completeness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Matched reporting patterns between drugs and events may predispose certain drugs to be disproportionally associated with adverse events. Therefore, SDR detected from matched drug-event source patterns in ICSR databases should be challenged during signal validation. Class SDR for drugs with differential source patterns (such as fatigue, asthenia, anaemia, thrombocytopenia, and neutropenia for all PARP inhibitors) usually involve correcting opposite drug-event source patterns.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fdsfr.2024.1497116","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:52:37Z","timestamp":1733467957000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Influence of differential source patterns in the detection of signals of disproportionate reporting for PARP inhibitors"],"prefix":"10.3389","volume":"4","author":[{"given":"Jordi","family":"Mestres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2165\/11316680-000000000-00000","article-title":"Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006","volume":"32","author":"Aagaard","year":"2009","journal-title":"Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40267-020-00762-6","article-title":"Adverse drug reaction reporting in Canada: consumer versus physician reports","volume":"36","author":"Al-Dweik","year":"2020","journal-title":"Drugs Ther. Perspect."},{"key":"B3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40264-015-0375-8","article-title":"A method for the minimization of competition bias in signal detection from spontaneous reporting databases","volume":"39","author":"Arnaud","year":"2016","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","article-title":"vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues","volume":"37","author":"Bergvall","year":"2014","journal-title":"Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.32614\/rj-2017-063","article-title":"openEBGM: an R implementation of the Gamma-Poisson shrinker data mining model","volume":"9","author":"Canida","year":"2017","journal-title":"R J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/14740338.2023.2254699","article-title":"Safety of PARP inhibitors as maintenance therapy in ovarian cancer","volume":"22","author":"Cecere","year":"2023","journal-title":"Exp. Opin. Drug Saf."},{"key":"B7","unstructured":"2024"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front. Drug Saf. Regul."},{"key":"B9","unstructured":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/bf03256796","article-title":"Data mining in drug safety: review of published threshold criteria for defining signals of disproportionate reporting","volume":"24","author":"Deshpande","year":"2010","journal-title":"Pharm. Med."},{"key":"B11","unstructured":"2024"},{"key":"B12","unstructured":"2024"},{"key":"B38","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The Reporting of a disproportionality Analysis for Drug Safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"Guo","year":"2022","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1101\/gad.291518.116","article-title":"PARPs and adp-ribosylation: recent advances linking molecular functions to biological outcomes","volume":"31","author":"Gupte","year":"2017","journal-title":"Genes Dev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B16","unstructured":"2024"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2021.05.012","article-title":"Risk of pneumonitis in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database","volume":"162","author":"Ma","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1038\/d41586-021-03714-w","article-title":"What\u2019s next for PARP inhibitors?","volume":"600","author":"Makin","year":"2021","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ajpath.2015.09.021","article-title":"Poly(ADP-Ribose) Polymerases \u2013 new players in the pathogenesis of exocrine pancreatic diseases","volume":"186","author":"Mart\u00ednez-Bosch","year":"2016","journal-title":"Am. J. Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/bs.adgen.2021.08.002","article-title":"PARP inhibitors in hereditary breast and ovarian cancer and other cancers: a review","volume":"108","author":"Mehta","year":"2021","journal-title":"Adv. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles?","volume":"37","author":"Michel","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"B24","doi-asserted-by":"publisher","first-page":"18817","DOI":"10.1038\/s41598-023-46275-w","article-title":"Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events","volume":"13","author":"Montes-Grajales","year":"2023","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2125.2012.04185.x","article-title":"Trends of reporting of serious vs non-serious adverse drug reactions over time: a study in the French PharmacoVigilance Database","volume":"74","author":"Moulis","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/curroncol29010029","article-title":"Safety profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Pagkali","year":"2022","journal-title":"Curr. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf."},{"key":"B29","unstructured":"2024"},{"key":"B30","volume-title":"Evolving roles of spontaneous reporting systems to assess and monitor drug safety","author":"Raschi","year":"2018"},{"key":"B31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40264-013-0075-1","article-title":"Choosing thresholds for statistical signal detection with the proportional reporting ratio","volume":"36","author":"Slattery","year":"2013","journal-title":"Drug Saf."},{"key":"B33","unstructured":"2024"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.3390\/ijms22084203","article-title":"Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy","volume":"22","author":"Valabrega","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B35","first-page":"1","article-title":"Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs","volume-title":"Adv. Inflam. Res.","author":"Weber","year":"1984"},{"key":"B36","unstructured":"2024"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2147\/DDDT.S147726","article-title":"Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials","volume":"11","author":"Zhou","year":"2017","journal-title":"Drug Des. devel. Ther."}],"container-title":["Frontiers in Drug Safety and Regulation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdsfr.2024.1497116\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:52:40Z","timestamp":1733467960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdsfr.2024.1497116\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":38,"alternative-id":["10.3389\/fdsfr.2024.1497116"],"URL":"https:\/\/doi.org\/10.3389\/fdsfr.2024.1497116","relation":{},"ISSN":["2674-0869"],"issn-type":[{"value":"2674-0869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"article-number":"1497116"}}